<unk>  is indicated in combination with appropriate antibacterial drugs in all age groups for treatment of inhalational anthrax due to Bacillus anthracis. It is also indicated in all age groups for post-exposure prophylaxis of inhalational anthrax when alternative therapies are not appropriate or are not available.
Obiltoxaximab
Atoltivimab
Regdanvimab
Sotrovimab
Odesivimab
Nirsevimab
Bebtelovimab
Lirentelimab